Brussels (June 29, 2017) – Today the European Commission published the new EU One Health Action Plan against Antimicrobial Resistance, which contains concrete actions for a more integrated, comprehensive and effective approach to combating AMR.

EGGVP – European Group for Generic Veterinary Products – welcomes this publication and is pleased to see it gives a stronger push on key areas, such as

  • Better addressing the ONE HEALTH APPROACH, since better coordination between both the human and veterinary sector are needed
  • Boosting innovation and research for the development of RAPID DIAGNOSTIC TESTS. The promotion of reliable and affordable sensitivity tools is crucial in order to facilitate rapid and accurate diagnosis and the choice of the most appropriate antimicrobial.
  • Shaping the GLOBAL AGENDA on AMR, since resistant bacteria do not know about borders and no country acting on its own can tackle the problem. International collective action is therefore essential.

EGGVP is much concerned about antimicrobial resistance and recognises the importance of setting appropriate and sustainable measures, based on policies aiming both at responsible use and prevention of spread or transmission of resistant bacteria. As a member of the European Platform for the Responsible Use of Medicines in Animals (EPRUMA), EGGVP fully supports the EPRUMA motto regarding the use of medicines in animals: “As little as possible, as much as necessary”.

Progress will not be achieved without concerted efforts from all stakeholders; consequently, EGGVP confirms its renewed and strengthened commitment to take necessary measures to contribute actively and responsively to control antimicrobial resistance; it will remain focused on continual improvement of the quality, safety and efficacy of veterinary medicines, and will keep on advocating prudent and responsible use of antimicrobials according to the Summary of Product Characteristics (SPC) approved by responsible national and European authorities.

EGGVP wishes to stress its support to the overarching goal of the new Commission Action Plan, which is to preserve the possibility of effective treatment of infections in humans and animals, while making the EU the best practice region in the world.